Related Experiment Video

Updated: Aug 3, 2025

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

18.8K

Role of RUNX2 in breast cancer development and drug resistance (Review)

Wentao Si1, Chen Kan1, Leisheng Zhang2,3

  • 1Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, P.R. China.

Oncology Letters
|April 10, 2023
PubMed

Insights

Runt-related transcription factor 2 (RUNX2) drives breast cancer stem cells (BCSCs) in aggressive breast cancer subtypes. Targeting RUNX2 in BCSCs may offer new strategies against breast cancer recurrence and drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Stem Cell Research

Background:

  • Breast cancer remains a leading cause of cancer death in women.
  • Breast cancer stem cells (BCSCs) contribute to tumor recurrence and treatment resistance.
  • Runt-related transcription factor 2 (RUNX2) is implicated in cancer metastasis and BCSCs.

Purpose of the Study:

  • To review the latest research on RUNX2 in breast cancer stem cells (BCSCs).
  • To explore the role of RUNX2 in breast cancer progression and drug resistance.
  • To provide insights for developing RUNX2-based diagnostics and therapeutics.

Main Methods:

  • Literature review of recent studies on RUNX2 and BCSCs.
  • Analysis of RUNX2 expression in different breast cancer subtypes.
  • Examination of RUNX2's association with drug resistance mechanisms.

Main Results:

  • RUNX2 is retained in invasive breast cancer subtypes, including triple-negative breast cancer.
  • RUNX2 expression correlates with breast cancer progression and resistance to therapies.
  • RUNX2 plays a significant role in the maintenance and function of BCSCs.

Conclusions:

  • RUNX2 is a key factor in breast cancer stem cell-mediated progression and drug resistance.
  • Targeting RUNX2 presents a potential therapeutic strategy for overcoming treatment challenges in breast cancer.
  • Further research into RUNX2's mechanisms could lead to novel clinical applications.
Keywords:
RUNX2breast cancerdrug resistanceregulatory mechanismstem cells

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K